Peptide education
Afamelanotide
Scenesse · Melanotan I analog · NDP-alpha-MSH · MC1 receptor agonist
Afamelanotide is a synthetic analog of alpha-MSH, the hormone that tells skin to make pigment, and it did something almost no compound in this catalog manages: it became an approved drug with randomized trials behind it. The approved form is Scenesse, a 16 mg implant placed under the skin by a trained professional every two months, for adults with erythropoietic protoporphyria, a rare disease in which daylight itself causes severe phototoxic pain. The label draws the line at that disease: no tanning indication, no general sun-tolerance claim, no self-use vial. A separate randomized vitiligo trial adds a genuine second signal, but as an add-on to phototherapy, not an approved use.
In the pivotal trials, adults with EPP receiving 16 mg implants every 60 days logged 64.1 versus 40.5 median pain-free hours in direct sunlight over 180 days in one study and 6.0 versus 0.75 hours outdoors over 270 days in the other. That is a real drug working for a real disease; it says nothing about cosmetic tanning or anything sold in a vial.
Overview
Quick answer
Afamelanotide is often pulled into tanning-peptide conversations because it activates melanocortin biology and can increase pigmentation. The approved product is narrower than that: Scenesse is a regulated 16 mg subcutaneous implant for EPP, not a cosmetic tanning injection, a melanotan vial, a libido drug, or a general sun-tolerance product.
What is afamelanotide?
A 13-amino-acid analog of alpha-MSH built to activate the MC1 receptor, the switch that tells skin cells to produce eumelanin. In the U.S. it exists as Scenesse, a controlled-release implant, and that product form is inseparable from the evidence: the trials tested the implant, not the molecule in the abstract.
What is it actually used for?
One thing: increasing pain-free light exposure in adults with EPP who have a history of phototoxic reactions. For people whose skin answers daylight with severe pain, the measured benefit is extra pain-free time outside, not a darker tan.
What dose and schedule show up in the label and trials?
The label is a single 16 mg implant every 2 months, placed by a trained healthcare professional. The pivotal trials used the same implant every 60 days, three implants across 180 days in one study and five across 270 days in the other.
Is it the same as melanotan or cosmetic tanning peptides?
The chemistry is related and the tanning market borrows the name, but the products are not the same. Scenesse is an administered, controlled-release implant with manufacturing, storage, and monitoring attached. Vials sold under melanotan names may claim the same molecule, but claiming is not matching: no controlled release, no verified identity, and no monitoring come with them.
Which claims need to stay separate?
The vitiligo result is the one worth knowing: in a 55-person randomized trial, adding four monthly 16 mg implants to NB-UVB phototherapy produced earlier and greater repigmentation, particularly in skin phototypes IV to VI. Everything else (cosmetic tanning, libido, general sun tolerance) has no trial record here at all, and even vitiligo is not an approved indication.
Reported practice
Commonly reported protocol
Label-pattern clinic use. Community-reported patterns, not verified by controlled human trials and not a use recommendation. Full use-pattern detail
Evidence
Evidence snapshot
DailyMed describes Scenesse as an MC1 receptor agonist indicated to increase pain-free light exposure in adults with EPP and a history of phototoxic reactions.
The label lists a single 16 mg subcutaneous implant administered every 2 months by trained health care professionals.
Randomized EPP trials used 16 mg implants every 60 days and reported longer pain-free light exposure and quality-of-life improvements.
Long-term observational and clinical-practice publications add useful follow-up context for EPP patients, not a broad cosmetic or wellness peptide.
In a 55-person randomized multicenter trial, participants received NB-UVB alone or NB-UVB plus four monthly 16 mg afamelanotide implants after the first month of phototherapy. Repigmentation began sooner and was greater with combination treatment, with the clearest difference in skin phototypes IV to VI.
The regulated implant has defined identity, dose, manufacturing, storage, implantation, adverse-event, and monitoring systems. That is different from a compounded vial, research-market vial, nasal product, or melanotan listing.
Claims
Common claims vs evidence
| Claim | Human evidence | Mechanistic evidence | Anecdotal evidence | Verdict |
|---|---|---|---|---|
| Afamelanotide increases pain-free light exposure in EPP. | This is the strongest supported use. The FDA label and pivotal EPP trials describe adults with EPP receiving 16 mg subcutaneous implants, with outcomes tied to pain-free exposure to direct sunlight or outdoor light. | MC1 receptor activation increases eumelanin production and may help explain why the drug can change light tolerance in EPP. | The sources include clinical-practice and long-term follow-up publications rather than forum or vendor reports. Those follow-up sources still stay focused on EPP patients. | Strong for adult EPP photoprotection when the product and population match Scenesse labeling and EPP trials. |
| Afamelanotide is a cosmetic tanning peptide. | The evidence base is EPP care, not cosmetic tanning. Pigmentation is part of the pharmacology and safety monitoring, but the approved indication is EPP-related pain-free light exposure. | MC1 receptor signaling can increase eumelanin, which explains why tanning claims attach to the name. Mechanism alone is not a basis for an approved or well-studied cosmetic-use claim. | Tanning-market discussion usually concerns melanotan-family products, not the EPP trials behind Scenesse. | Misleading when stated broadly. The Scenesse evidence is about a rare phototoxic disease, not ordinary cosmetic tanning. |
| Scenesse evidence applies to melanotan, research vials, or compounded products. | The label, approval letter, and EPP trials describe a regulated Scenesse implant. They leave open the identity, sterility, dose, release profile, storage, and clinical safety of other products sold under related melanocortin names. | This is mostly a product and manufacturing question. Receptor activity cannot show that another product matches the implant used in trials. | Gray-market listings may use the afamelanotide name or broader melanocortin discussion, but those listings do not verify the products. | No. Scenesse data explain the regulated implant, not unrelated vials or nasal products. |
| Afamelanotide has been studied for vitiligo. | A randomized multicenter trial enrolled 55 adults with nonsegmental vitiligo and skin phototypes III to VI. Everyone received NB-UVB; 28 participants also received four monthly 16 mg afamelanotide implants beginning after one month of phototherapy. Repigmentation started sooner and was greater in the combination group, particularly in phototypes IV to VI. An earlier four-person report found the same general pattern. | Afamelanotide activates melanocortin signaling and promotes eumelanin production. In these studies it was paired with NB-UVB, so the clinical result cannot show how well afamelanotide would work by itself. | Online accounts involving Melanotan-1 vials or nasal products do not reproduce the identity, release profile, administration, or monitoring of the controlled implant used in the studies. | A real positive human signal exists for afamelanotide implants added to NB-UVB, especially in darker skin phototypes. Vitiligo is not a current approved Scenesse indication, and these results are not proof for gray-market products. |
| The safety profile is simple because Scenesse is approved. | Approval gives a regulated label, not a blank safety pass. The label highlights hypersensitivity and anaphylaxis reports, skin monitoring for nevi and ephelides, implant-site reactions, pregnancy data limits, and unknown renal or hepatic impairment effects. | Pigment changes are expected from MC1 receptor pharmacology, which is why skin monitoring is part of the label rather than an afterthought. | Long-term and clinical-practice EPP publications are helpful, but they still describe selected treated populations and regulated-product care. | The label and EPP follow-up literature are the right safety sources, not casual tanning-peptide language. |
Bottom line
Main takeaway
Afamelanotide is the real thing, an approved drug, but for one rare light-sensitivity disease and only as a clinic-administered implant. It is not a tanning product that happened to get approved.
Hold three things apart: the molecule, the Scenesse implant, and the melanotan-labeled products sold online. The trial numbers belong to the middle one, and neither the mechanism nor a vendor label transfers them.
Anchor on the DailyMed label, the FDA approval letter, and the NEJM EPP trials, then add the long-term observational follow-up and the JAMA Dermatology practice cohort. The 55-person vitiligo trial is the legitimate second signal; read it as combination-therapy evidence, not monotherapy and not an indication.
Identity
What it is
Afamelanotide is a tridecapeptide: thirteen amino acids modeled on alpha-MSH. The Scenesse label classifies it as a melanocortin receptor agonist that binds predominantly to MC1 receptors, the pathway that drives eumelanin production.
The disease explains the drug. EPP leaves people unable to tolerate ordinary daylight, because visible light triggers phototoxic reactions and severe pain. A drug that raises eumelanin and adds pain-free hours outdoors does something measurable for them, and the trials measured it: in one, median pain-free time in direct sunlight over 180 days was 64.1 hours on Scenesse against 40.5 on vehicle; in the other, median pain-free outdoor time over 270 days was 6.0 hours against 0.75, with quality of life improving alongside.
What afamelanotide is not is a self-use tanning peptide. Scenesse is implanted by a trained professional, stored refrigerated, designed to release over days, and monitored with twice-yearly full-body skin exams. None of that transfers to a vial, a spray, or a melanotan listing, and neither do the results.
How people talk about it online
Most afamelanotide search traffic arrives from the tanning world: people who heard a melanotan compound won FDA approval and want to know how to get it. What they actually find is a prescription implant for a rare disease, administered by specialists on a fixed schedule, and that mismatch answers most of the questions being asked.
Vitiligo communities have a more grounded interest, since a randomized trial did show faster repigmentation when implants were added to NB-UVB. But that was combination therapy under trial conditions, vitiligo is not an approved indication, and the gray-market vials discussed in the same breath reproduce none of the trial product's controls.
Use context
Routes, doses, and cycle patterns
The label-reported use pattern is Scenesse: a single 16 mg implant placed subcutaneously every 2 months by trained health care professionals. Pivotal EPP trials used 16 mg implants every 60 days, with three implants over 180 days in one study and five implants over 270 days in another. The label and trial data do not supply a consumer injection, nasal, loading, maintenance, or cycle schedule.
Human studies and product labels
Current Scenesse label
- Purpose
- Increase pain-free light exposure in adults with EPP and phototoxic reactions
- Context
- FDA label / DailyMed prescribing information
- Route
- Subcutaneous implant above the anterior supra-iliac crest
- Amount
- One implant containing 16 mg afamelanotide
- Frequency
- Every 2 months
- Duration
- Labeled treatment schedule; not described as a short cycle
The label assigns Scenesse administration to trained health care professionals and keeps sun and light protection measures in place during treatment.
Study CUV039
- Purpose
- Pain-free direct sunlight exposure in EPP
- Context
- Vehicle-controlled clinical trial summarized in the label
- Route
- Subcutaneous implant
- Amount
- 16 mg afamelanotide
- Frequency
- Every 2 months
- Duration
- Three implants with 180 days of follow-up
The label reports median pain-free direct sunlight time from 10 am to 6 pm over 180 days of 64.1 hours with Scenesse versus 40.5 hours with vehicle.
Study CUV029
- Purpose
- Pain-free outdoor exposure in EPP
- Context
- Vehicle-controlled clinical trial summarized in the label
- Route
- Subcutaneous implant
- Amount
- 16 mg afamelanotide
- Frequency
- Every 2 months
- Duration
- Five implants with 270 days of follow-up
The label reports median pain-free outdoor time between 10 am and 3 pm over 270 days of 6.0 hours with Scenesse versus 0.75 hours with vehicle.
Long-term EPP follow-up
- Purpose
- Quality-of-life and treated-patient follow-up context
- Context
- Long-term observational and clinical-practice publications
- Route
- Scenesse / afamelanotide implant use in EPP care
- Amount
- 16 mg implant in the treated-product context
- Frequency
- Repeated implant treatment in EPP follow-up
- Duration
- Long-term observation and clinical-practice follow-up
These publications help with durability, quality-of-life, and treated-patient context. They still describe EPP care, not cosmetic or gray-market use.
Randomized vitiligo combination trial
- Purpose
- Repigmentation of nonsegmental vitiligo
- Context
- Randomized multicenter comparison of combination therapy with NB-UVB alone
- Route
- Subcutaneous controlled-release implant plus NB-UVB phototherapy
- Amount
- 16 mg afamelanotide per implant
- Frequency
- One implant monthly for four months, starting after one month of NB-UVB
- Duration
- Six-month study period with NB-UVB continued in both groups
The study enrolled 55 adults. Combination treatment produced earlier and greater repigmentation than NB-UVB alone, with a stronger effect in skin phototypes IV to VI. It tested a controlled implant as part of combination therapy, not a vial, nasal product, or afamelanotide monotherapy.
Real-world discussion
Label-pattern clinic use
- Purpose
- Photoprotection in EPP, with tanning spillover discussion
- Context
- Specialty clinics and community discussion
- Route
- Subcutaneous implant
- Amount
- The approved pattern is a single 16 mg implant every two months
- Frequency
- Every two months in the labeled pattern
- Duration
- Ongoing in labeled use; seasonal timing is real-world practice
Afamelanotide is an approved prescription implant, so real-world use follows the label; community interest in it for cosmetic tanning runs into the reality that it is an administered implant, not a self-use vial. Reported as context, not a recommendation.
What varies
- Indication: adult EPP with phototoxic reactions is a different question from tanning, libido, vitiligo, or everyday sun exposure.
- Product: the evidence is for a regulated Scenesse implant, not every vial, spray, or compounded product using a melanocortin name.
- Route: the cited label and pivotal trials use a subcutaneous implant, not ordinary self-injection or nasal delivery.
- Amount: the label and trials repeatedly center on a 16 mg implant.
- Duration: pivotal trials followed patients over 180 or 270 days, while the label describes ongoing every-2-month administration rather than a short cycle.
Human data
Human evidence
This is one of the deepest human evidence records in the peptide catalog, and one of the narrowest. Randomized placebo-controlled trials, the FDA label, long-term observational follow-up, and a clinical-practice cohort all point the same way: more pain-free light exposure and better quality of life for adults with EPP on 16 mg implants. The vitiligo record stands apart from that: a 55-person randomized trial in which implants added to NB-UVB produced earlier and greater repigmentation, concentrated in skin phototypes IV to VI. Beyond those two settings there is no human evidence for tanning, libido, wellness, or any product that is not the implant.
Evidence maturity
Afamelanotide is a rare case in this catalog: randomized trials and FDA approval back one narrow EPP indication, and every other use sits outside that evidence.
Synthetic alpha-MSH analog that binds predominantly MC1 receptors and drives eumelanin production.
Multicenter randomized placebo-controlled trials reported more pain-free light exposure in adults with EPP.
Approved in 2019 as Scenesse, a 16 mg subcutaneous implant for adult EPP photoprotection.
Long-term observational and clinical-practice publications track EPP patients receiving repeated implants.
A 55-person randomized vitiligo trial showed faster repigmentation when implants were added to NB-UVB, but vitiligo, tanning, and other uses remain unapproved and unproven.
| Study / evidence area | Population | Design | Product context | Main outcome | Limitations | Weight |
|---|---|---|---|---|---|---|
| Scenesse FDA label and approval | Adults with EPP and a history of phototoxic reactions | FDA approval and prescribing-information source | Approved Scenesse implant | The label and approval define the indication, 16 mg implant strength, every-2-month subcutaneous schedule, warnings, and monitoring context. | Approval does not cover cosmetic tanning, vitiligo, libido, ordinary sun-tolerance, compounded-product, or gray-market melanocortin claims. | Strong |
| Afamelanotide for erythropoietic protoporphyria | People with EPP in European Union and United States trials | Multicenter randomized double-blind placebo-controlled trials | Subcutaneous afamelanotide implants in controlled trials | The trials reported increased pain-free sunlight exposure and improved quality of life with 16 mg implants administered every 60 days. | The trials studied EPP pain-free light exposure with regulated implants. They leave consumer tanning, melanotan substitution, and general photoprotection outside the evidence. | Strong |
| Long-term observational EPP treatment | Ambulatory patients with EPP treated in long-term follow-up | Observational follow-up | Afamelanotide implant treatment in EPP care | The publication adds longer follow-up and quality-of-life context for EPP patients receiving repeated afamelanotide implants. | Observational data are less controlled than randomized trials and still do not apply to non-EPP or non-Scenesse product claims. | Moderate |
| EPP clinical-practice cohort | Patients with EPP treated in clinical practice | Clinical-practice cohort | Afamelanotide in routine EPP care | The cohort supports improved EPP outcomes in treated clinical-practice settings and helps interpret post-approval use. | Clinical-practice findings do not back separate dermatology, libido, tanning-market, or separate product claims. | Moderate |
| Afamelanotide plus NB-UVB for vitiligo | 55 adults with nonsegmental vitiligo and skin phototypes III to VI | Randomized multicenter comparison with NB-UVB monotherapy | Four monthly 16 mg controlled-release implants added after one month of NB-UVB | Repigmentation began sooner and was greater with afamelanotide plus NB-UVB than with NB-UVB alone. The treatment difference was more pronounced in participants with skin phototypes IV to VI. | Afamelanotide was tested as an addition to phototherapy, not alone. The trial was small, vitiligo is not a current approved indication, and the controlled implants do not establish the safety or effectiveness of gray-market vials or nasal products. | Moderate |
Use context
Reported use context
The reliable reported-use facts come from the approved Scenesse implant and EPP trial program. They describe implant-based EPP care, not reliable off-label clinic, forum, Reddit, vendor, or gray-market dosing patterns.
Study and label context
One 16 mg implant every 2 months for adults with EPP and phototoxic-reaction history.
16 mg implants every 60 days, with three or five implants depending on the trial.
After one month of NB-UVB, 28 of 55 participants received four monthly 16 mg afamelanotide implants while phototherapy continued; the comparison group continued NB-UVB alone.
Real-world discussion
Real-world Scenesse use is commonly described as seasonal: 16 mg implants roughly every 2 months timed to the sunnier months, individualized in specialist EPP care.
Community schedules typically describe around 0.5 to 1 mg per injection, daily or every other day during an initial tanning phase, then once or twice weekly as maintenance. These are unverified reports about unapproved vials, not label or trial regimens.
Cautions
Safety and unknowns
- The label reports serious hypersensitivity reactions, including anaphylaxis, and notes that implant removal may be needed if a serious reaction occurs.
- Scenesse may darken pre-existing nevi and ephelides, so the label recommends full-body skin examinations twice yearly to monitor pre-existing and new pigmented lesions.
- Common adverse reactions in the label include implant-site reactions, nausea, oropharyngeal pain, cough, fatigue, dizziness, skin hyperpigmentation, somnolence, melanocytic nevus, respiratory-tract infection, non-acute porphyria, and skin irritation.
- Pregnancy and lactation data are limited, pediatric safety and effectiveness are not established, and renal or hepatic impairment effects on pharmacokinetics are unknown in the label.
- The EPP data leave open whether compounded, research-market, nasal, or melanotan-family products have matching identity, sterility, release profile, impurities, dose accuracy, storage, or adverse-event reporting.
Product quality
A vial label is only a starting point
Scenesse is a regulated, sterile, bioresorbable implant with a defined 16 mg strength, controlled-release design, refrigerator storage, and trained implantation process.
Name similarity does not mean implant strength, controlled-release behavior, sterility, storage, implantation process, or EPP trial equivalence.
Product identity
The evidence is for Scenesse and EPP trials, not every melanocortin product using a related name.
Release profile
A controlled-release implant is different from a vial, nasal spray, or other non-label product form.
Sterility and implantation
The label describes aseptic implantation by trained professionals; that cannot be assumed for unregulated products.
Monitoring system
Skin exams, hypersensitivity monitoring, adverse-event reporting, and product removal instructions are part of the regulated-product context.
Mechanism
How it is proposed to work
Afamelanotide mimics alpha-MSH signaling and binds predominantly to MC1 receptors. MC1 activation can increase eumelanin, the brown-black pigment involved in skin photoprotection, which helps explain why Scenesse can improve pain-free light exposure in EPP.
Scenesse is a controlled-release subcutaneous implant, so its route and exposure profile are part of the product behavior, not just the amino-acid sequence.
The label reports high variability after a single implant in healthy adults, with median time to maximum concentration around 36 hours and an apparent half-life of about 15 hours in the controlled-release implant context.
MC1 receptor pharmacology explains pigmentation and skin-monitoring issues. Libido, vitiligo, cosmetic tanning, and melanotan-family products are different questions from EPP care.
FAQ
Common questions
Is afamelanotide a tanning peptide?
No. The approved product is Scenesse for EPP photoprotection. It should not be read as evidence for cosmetic tanning, melanotan-family products, libido claims, or ordinary sun-tolerance use.
Does Scenesse evidence apply to melanotan or research-market products?
No. Scenesse evidence is attached to a regulated approved product, specific product design, and EPP trial populations. Non-approved products have separate identity, sterility, labeling, and oversight problems.
Is afamelanotide approved for vitiligo or general photoprotection?
Not in the cited Scenesse label sources. Vitiligo, cosmetic, and general photoprotection questions need their own direct evidence before being grouped with Scenesse's EPP indication.
Details
Technical details
Sources
References
- 1.
DailyMed. SCENESSE- afamelanotide implant prescribing information 2026.
Accessed 2026-06-09.
Current structured label source for Scenesse indication, MC1 receptor mechanism, warnings, clinical-trial safety summary, and product identity.
- 2.
FDA. Scenesse (afamelanotide) implant NDA approval letter 2019.
Accessed 2026-06-09.
FDA approval letter for Scenesse as an afamelanotide product used to increase pain-free light exposure in adults with EPP and history of phototoxic reactions.
- 3.
PubMed. Afamelanotide for Erythropoietic Protoporphyria 2015.
doi:10.1056/NEJMoa1411481 PMID:26132941 Accessed 2026-06-09.
Pivotal randomized controlled human evidence in erythropoietic protoporphyria evaluating pain-free light exposure and quality-of-life outcomes.
- 4.
PubMed. Long-term observational study of afamelanotide in 115 patients with erythropoietic protoporphyria 2015.
doi:10.1111/bjd.13598 PMID:25494545 Accessed 2026-06-09.
Long-term observational EPP source used for quality-of-life and follow-up context, not for broad cosmetic or non-label claims.
- 5.
PubMed. Association of Afamelanotide With Improved Outcomes in Patients With Erythropoietic Protoporphyria in Clinical Practice 2020.
doi:10.1001/jamadermatol.2020.0352 PMID:32186677 Accessed 2026-06-09.
Clinical-practice cohort evidence in EPP used for real-world outcome context and safety-boundary framing.
- 6.
Randomized multicenter vitiligo trial. Lim et al., JAMA Dermatology, 2015, afamelanotide plus NB-UVB for vitiligo
Human vitiligo trial design, implant pattern, repigmentation results, and skin-phototype finding
- 7.
Preliminary vitiligo case series. Grimes et al., JAMA Dermatology, 2013, afamelanotide plus NB-UVB for vitiligo
Four-patient precursor report and monthly controlled-implant pattern